COMP <GO>
KYMR vs RGEN // EV/EBITDA & P/E VALUATION
Kymera Therapeutics Inc. (NASDAQ) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: KYMR 3
— RGEN 7
■ METRIC PARITY
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
valuation
—
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. RGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | RGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 2.30% | -23.70 | RGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 0.88% | -3.18 | RGEN | /fcf-yield <GO> |
| Operating Margin | -60.00% | 1.80% | -61.80 | RGEN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 1.60% | +66.40 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | -3.30% | -13.40 | RGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.31 | +16.69 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.6 | 56.7 | +4.90 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.04 | -0.09 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $10.69B | -$500.3M | RGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | RGEN REV | KYMR GROSS % | RGEN GROSS % | KYMR FCF | RGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $0 | 0.0% | — | -$234.3M | $93.9M |
| FY 2024 | $47.1M | $0 | 0.0% | — | -$207.3M | $149.7M |
| FY 2023 | $78.6M | $0 | — | — | -$106.4M | $113.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
RGEN // BETA 1.04